|
gptkbp:instanceOf
|
gptkb:chemical_compound
MEK inhibitor
|
|
gptkbp:bioavailability
|
high (in preclinical models)
|
|
gptkbp:CASNumber
|
391210-10-9
|
|
gptkbp:category
|
experimental cancer drug
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Phase_I
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:hasMolecularFormula
|
C16H14F3IN2O4
|
|
gptkbp:hasSMILES
|
C1=CC(=C(C=C1N)F)I.C1=CC(=C(C=C1N)F)I
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PD0325901
|
|
gptkbp:inhibitedBy
|
gptkb:MAP2K1
gptkb:MAP2K2
|
|
gptkbp:IUPACName
|
(R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
|
|
gptkbp:mechanismOfAction
|
inhibits MAPK/ERK pathway
|
|
gptkbp:molecularWeight
|
482.195 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEBI:90222
gptkb:CHEMBL437081
9915743
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:studiedBy
|
gptkb:cancer
gptkb:neurofibromatosis_type_1
melanoma
|
|
gptkbp:synonym
|
gptkb:PD-325901
gptkb:PD_0325901
|
|
gptkbp:target
|
gptkb:MEK1
gptkb:MEK2
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:used_in_cell_line
|
gptkb:A375
gptkb:SK-MEL-28
|
|
gptkbp:bfsParent
|
gptkb:MEK2
gptkb:CHIR99021
|
|
gptkbp:bfsLayer
|
6
|